GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Gloria Pharmaceuticals Co Ltd (SZSE:002437) » Definitions » Valuation Rank

Harbin Gloria Pharmaceuticals Co (SZSE:002437) Valuation Rank


View and export this data going back to 2010. Start your Free Trial

What is Harbin Gloria Pharmaceuticals Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Harbin Gloria Pharmaceuticals Co Valuation Rank Related Terms

Thank you for viewing the detailed overview of Harbin Gloria Pharmaceuticals Co's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Gloria Pharmaceuticals Co (SZSE:002437) Business Description

Traded in Other Exchanges
N/A
Address
Beijing Road No 29, Harbin Economic and Technological Development Zone, Harbin, CHN, 150025
Harbin Gloria Pharmaceuticals Co Ltd is a tech biopharmaceutical enterprise. It is engaged in the research, development, production, and sale of pharmaceutical products primarily in China. The company offers cardiovascular drugs; cardiac cerebrovascular medication; vitamins and minerals; urinary tract drugs; urinary system medication; anti-tumor medication; endocrine system drugs; anti-infective drugs; digestive system medication; respiratory medication; and other medications.
Executives
Guo Yun Pei Independent director
Wang Yu Supervisors
Yang Hong Bing Director
Diao Xiu Qiang Directors, executives
Liu Yue Yin Securities Affairs Representative
Guo Lei Feng Directors, Directors, and Executives
Li Jun Ling Director
Yang Hai Feng Executives
Zhang Su Mei Supervisors
Zhu Ji Man Director